|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Alberta Cancer Board CIHR |
|---|---|
| Information provided by: | Alberta Cancer Board |
| ClinicalTrials.gov Identifier: | NCT00124930 |
Purpose
The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.
| Condition | Intervention | Phase |
|---|---|---|
|
Nausea Neoplasms |
Drug: Olanzapine Drug: Haldol |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Randomized Double-Blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-Peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer |
| Estimated Enrollment: | 80 |
| Study Start Date: | May 2005 |
| Estimated Study Completion Date: | June 2008 |
| Estimated Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
The purpose of this study is to compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | 18731, MCT 71119, ISRCTN58624349 |
| Study First Received: | July 27, 2005 |
| Last Updated: | October 3, 2008 |
| ClinicalTrials.gov Identifier: | NCT00124930 History of Changes |
| Health Authority: | Canada: Health Canada |
|
olanzapine haldol cancer |
nausea second line treatment refractory nausea |
|
Neurotransmitter Agents Vomiting Tranquilizing Agents Signs and Symptoms, Digestive Olanzapine Psychotropic Drugs Antiemetics Central Nervous System Depressants Antipsychotic Agents |
Serotonin Uptake Inhibitors Serotonin Haloperidol Signs and Symptoms Haloperidol decanoate Dopamine Dopamine Agents Nausea Peripheral Nervous System Agents |
|
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Signs and Symptoms, Digestive Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Olanzapine Psychotropic Drugs Antiemetics Haloperidol Signs and Symptoms Therapeutic Uses Nausea |
Tranquilizing Agents Gastrointestinal Agents Central Nervous System Depressants Dopamine Antagonists Antipsychotic Agents Serotonin Uptake Inhibitors Pharmacologic Actions Neoplasms Serotonin Agents Autonomic Agents Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |
